Trial · NCT04704050
Results by group110
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 110
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Post-ablation Atrial Fibrillation Recurrence | Treatment Group | 2 | Participants | ||
| Post-ablation Atrial Fibrillation Recurrence | Control Group | 1 | Participants | ||
| Post-ablation Atrial Fibrillation Recurrence Documented by an AAD Initiation | Treatment Group | 1 | Participants | ||
| Post-ablation Atrial Fibrillation Recurrence Documented by an AAD Initiation | Control Group | 2 | Participants | ||
| Atrial Fibrillation Episodes | Treatment Group | 7.5 | Standard Deviation 1.73 | Scores on a scale | |
| Atrial Fibrillation Episodes | Control Group | 7.8 | Standard Deviation 2.17 | Scores on a scale | |
| Repeat Cardiac Ablation | Treatment Group | 1 | Participants | ||
| Repeat Cardiac Ablation | Control Group | 0 | Participants | ||
| Cardioversion | Treatment Group | 2 | Participants | ||
| Cardioversion | Control Group | 1 | Participants | ||
| Atrial Fibrillation Burden | Treatment Group | 9 | Standard Deviation 4.55 | Percentage of time | |
| Atrial Fibrillation Burden | Control Group | 4.5 | Standard Deviation 5.8 | Percentage of time | |
| Quality of Life (Online Questionnaire Form) | Treatment Group | 8.8 | Standard Deviation 1.30 | Scores on a scale | |
| Quality of Life (Online Questionnaire Form) | Control Group | 10 | Standard Deviation 0 | Scores on a scale | |
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Treatment Group | Anemia | 1 | Events | |
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Control Group | Anemia | 0 | Events | |
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Treatment Group | Fatigue | 1 | Events | |
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Control Group | Fatigue | 0 | Events | |
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Treatment Group | Hypoxemia | 1 | Events | |
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Control Group | Hypoxemia | 0 | Events |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04704050/results